Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Employees - 23, CEO - Margaret Alexander, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 1.64, Piotroski Score(max is 10): 2, Working Capital: $82159000, Total Assets: $150934000, Retained Earnings: $-321713000, EBIT: -42074000, Total Liabilities: $20274000, Revenue: $7252000

AryaFin Target Price - $-1.82 - Current Price $ - Analyst Target Price $